Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Mustang Bio Inc (MBIO)

Mustang Bio Inc (MBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 263,238
  • Shares Outstanding, K 91,402
  • Annual Sales, $ 0 K
  • Annual Income, $ -60,020 K
  • 60-Month Beta 1.72
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.00
Trade MBIO with:

Options Overview

Details
  • Implied Volatility 90.04%
  • Historical Volatility 40.63%
  • IV Percentile 13%
  • IV Rank 21.92%
  • IV High 248.00% on 09/25/20
  • IV Low 45.70% on 09/14/21
  • Put/Call Vol Ratio 0.05
  • Today's Volume 389
  • Volume Avg (30-Day) 270
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 26,305
  • Open Int (30-Day) 18,606

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.18
  • Number of Estimates 3
  • High Estimate -0.15
  • Low Estimate -0.20
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +21.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.61 +10.34%
on 08/19/21
3.09 -6.80%
on 08/31/21
+0.01 (+0.35%)
since 08/17/21
3-Month
2.59 +11.20%
on 08/16/21
3.69 -22.06%
on 06/28/21
-0.55 (-16.03%)
since 06/17/21
52-Week
2.42 +19.01%
on 10/26/20
5.22 -44.83%
on 01/25/21
-0.72 (-20.00%)
since 09/17/20

Most Recent Stories

More News
Mustang Bio to Participate in Three September 2021 Investor Conferences

Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic...

MBIO : 2.88 (+3.97%)
FBIO : 3.35 (+2.13%)
Mustang Bio Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights

Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic...

MBIO : 2.88 (+3.97%)
FBIO : 3.35 (+2.13%)
Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic...

MBIO : 2.88 (+3.97%)
FBIO : 3.35 (+2.13%)
Mustang Bio Awarded Massachusetts Life Sciences Center Tax Incentive

Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic...

MBIO : 2.88 (+3.97%)
FBIO : 3.35 (+2.13%)
Mustang Bio to Present at the Raymond James Human Health Innovation Conference

Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic...

MBIO : 2.88 (+3.97%)
FBIO : 3.35 (+2.13%)
Mustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

Webinar to be held Tuesday, June 15, 2021, at 1:00 p.m. ET

MBIO : 2.88 (+3.97%)
FBIO : 3.35 (+2.13%)
Thinking about buying stock in Express, Mustang Bio, Senseonics, United Microelectronics, or IQIYI?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EXPR, MBIO, SENS, UMC, and IQ.

SENS : 3.81 (-0.26%)
IQ : 8.70 (-2.36%)
MBIO : 2.88 (+3.97%)
EXPR : 5.37 (-3.94%)
UMC : 11.73 (-2.49%)
Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors

Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic...

MBIO : 2.88 (+3.97%)
FBIO : 3.35 (+2.13%)
Mustang Bio Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic...

MBIO : 2.88 (+3.97%)
FBIO : 3.35 (+2.13%)
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress

Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic...

MBIO : 2.88 (+3.97%)
FBIO : 3.35 (+2.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mustang Bio, Inc. a subsidiary of Fortress Biotech, Inc., is a clinical'stage biopharmaceutical company. It focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient's own immune system to eliminate cancer cells. Mustang Bio, Inc. is based...

See More

Key Turning Points

3rd Resistance Point 3.10
2nd Resistance Point 3.00
1st Resistance Point 2.94
Last Price 2.88
1st Support Level 2.78
2nd Support Level 2.68
3rd Support Level 2.62

See More

52-Week High 5.22
Fibonacci 61.8% 4.15
Fibonacci 50% 3.82
Fibonacci 38.2% 3.49
Last Price 2.88
52-Week Low 2.42

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar